Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Republic of Korea.
J Clin Oncol. 2010 Jan 20;28(3):487-92. doi: 10.1200/JCO.2009.24.5480. Epub 2009 Dec 14.
Active tobacco smoking has been associated with the incidence of epidermal growth factor receptor (EGFR) mutations. However, the impact of environmental tobacco smoke (ETS) on EGFR mutations has been unknown. We investigated an association between ETS exposure and EGFR mutations in never smokers with non-small-cell lung cancer (NSCLC).
We enrolled 179 consecutive never smokers who were newly diagnosed with NSCLC. The history of ETS exposure was obtained with a standardized questionnaire that included exposure period, place, and duration. The nucleotide sequences of exons 18 to 21 on EGFR gene were determined using nested polymerase chain reaction amplification.
The incidence of EGFR mutations was significantly lower in patients with ETS exposure than in those without (38.5% v 61.4%; P = .008). In a logistic regression model that adjusted for sex and histology, an adjusted odds ratio (AOR) for the risk of EGFR mutations with exposure to ETS was 0.40 (95% CI, 0.20 to 0.81; P = .011). In quartile groups based on total smoker-year, the AORs for the lowest- to highest-quartile groups were 0.59 (95% CI, 0.23 to 1.49), 0.50 (95% CI, 0.17 to 1.50), 0.48 (95% CI, 0.20 to 1.18), and 0.22 (95% CI, 0.08 to 0.62; P(trend) = .028). Among the types of ETS exposure, adulthood ETS and household ETS were significantly associated with the incidence of EGFR mutations. Patients with ETS exposure showed a lower response rate to EGFR tyrosine kinase inhibitors than did patients without ETS exposure (24.6% v 44.8%; P = .053).
ETS exposure is negatively associated with EGFR mutations in never smokers with NSCLC.
主动吸烟已与表皮生长因子受体(EGFR)突变的发生有关。然而,环境烟草烟雾(ETS)对 EGFR 突变的影响尚不清楚。我们研究了从不吸烟的非小细胞肺癌(NSCLC)患者中 ETS 暴露与 EGFR 突变之间的关系。
我们纳入了 179 例新诊断为 NSCLC 的连续从不吸烟者。通过包括暴露期、地点和持续时间的标准化问卷获得 ETS 暴露史。使用巢式聚合酶链反应扩增确定 EGFR 基因外显子 18 至 21 的核苷酸序列。
有 ETS 暴露的患者 EGFR 突变的发生率明显低于无 ETS 暴露的患者(38.5%对 61.4%;P=0.008)。在调整性别和组织学的逻辑回归模型中,ETS 暴露的 EGFR 突变风险的调整比值比(AOR)为 0.40(95%CI,0.20 至 0.81;P=0.011)。根据总吸烟年数进行四分位组分析,最低至最高四分位组的 AOR 分别为 0.59(95%CI,0.23 至 1.49)、0.50(95%CI,0.17 至 1.50)、0.48(95%CI,0.20 至 1.18)和 0.22(95%CI,0.08 至 0.62;P(趋势)=0.028)。在 ETS 暴露类型中,成年 ETS 和家庭 ETS 与 EGFR 突变的发生显著相关。有 ETS 暴露的患者对 EGFR 酪氨酸激酶抑制剂的反应率低于无 ETS 暴露的患者(24.6%对 44.8%;P=0.053)。
从不吸烟的 NSCLC 患者中,ETS 暴露与 EGFR 突变呈负相关。